Tue, Jan 27, 2015, 2:41 PM EST - U.S. Markets close in 1 hr 19 mins

Recent

% | $
Quotes you view appear here for quick access.

Santarus, Inc. (SNTS) Message Board

  • hofno2003 hofno2003 Sep 26, 2012 5:39 AM Flag

    Metformin (Glumetza): "The" new Cancer Drug

    Artikel about Metformin (Glumetza) suggests that this may be effective as cancer drug.
    To get the article please google with the term:
    "Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug"

    Hofno

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Pamela Goodwin, an oncologist at Toronto’s Mount Sinai Hospital, is leading a trial in 3,582 breast-cancer patients at 300 locations. Data analysis from the five-year study may start in 2016 or 2017, according to Goodwin, who said she was ready to start on the research a decade ago, but lacked financial support from companies, including one that still had a patented version. She declined to identify the company.

      “When they realized the results wouldn’t be available until they lost their patent, they pulled out,” said Goodwin, whose $25 million study is supported by the Canadian and U.S. governments as well as not-for-profit groups including the Canadian Cancer Society, the Breast Cancer Research Foundation and Cancer Research UK. Apotex Inc., a Toronto-based maker of generic medicines, is supplying metformin and a placebo used in the trial.

      “All of the evidence has just become stronger while we waited,” said Goodwin, who is also a professor of medicine at the University of Toronto.

    • REALLY very interesting! I do not know if it/s applicable to Santarus???
      Thanks for your greatest input.

 
SNTS
31.96-0.01(-0.03%)Dec 31 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.